Ahn Kung, Baek Kyung-Wan, Yun Kyeongeui, Oh Yunseok, Kim Yong Sung, Im Eunok, Lee Yunna, Choi Jieun, Song Eun-Ji, Park Yong-Soo, Lee Dong Ho, Lee Wonsuk, Lee Do Yup, Han Kyudong, Ahn Yong Ju
HuNBiome Co., Ltd, R&D Center, Seoul, Republic of Korea.
Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju, Republic of Korea.
Sci Rep. 2025 Jul 1;15(1):21103. doi: 10.1038/s41598-025-03860-5.
Inflammatory bowel disease (IBD) is a chronic condition characterized by intestinal inflammation and dysbiosis, with limited treatment options and significant challenges in long-term management. This study investigated the therapeutic potential of novel strains belonging to Bifidobacterium longum and Limosilactobacillus species, in a dextran sodium sulfate (DSS)-induced mouse model of colitis. In this study, our primary objective was to determine whether ingestion of these strains alleviates colitis symptoms and, if so, to elucidate how they restored gut microbial balance and modulated microbial metabolic functions. In most probiotic-treated groups, colitis disease activity index scores were significantly improved and colon length was preserved, with strains CBA7106 and BBH exhibiting efficacy comparable to that of the Lactobacillus rhamnosus GG (used as a positive control). Moreover, histological analyses confirmed reduced inflammation and enhanced mucosal integrity. Microbial diversity assessments demonstrated a marked restoration of gut microbial composition, highlighted by increased abundances of beneficial taxa such as Lactobacillus and Akkermansia. Metabolomic profiling identified key anti-inflammatory metabolites, including 6-hydroxycaproic acid, indole-3-lactic acid, and choline, which were significantly elevated in the probiotic-treated groups. Notably, functional analyses using PICRUSt2 revealed a sustained decrease in the siderophore biosynthesis pathway (ko01053), suggesting that these candidate probiotic strains may inhibit siderophore production-a pivotal mechanism by which pathogenic bacteria aggravate intestinal inflammation. Taken together, these findings indicate that the candidate probiotic strains CBA7106 and BBH effectively mitigate DSS-induced colitis by modulating the gut microbiota, promoting the production of anti-inflammatory metabolites, and suppressing siderophore biosynthesis. This study provides valuable insights into the development of targeted probiotic therapies for IBD, underscoring their potential as a complementary approach to restoring intestinal health and reducing inflammation. Further clinical studies are warranted to validate these observations in human populations.
炎症性肠病(IBD)是一种以肠道炎症和生态失调为特征的慢性疾病,治疗选择有限,长期管理面临重大挑战。本研究在葡聚糖硫酸钠(DSS)诱导的小鼠结肠炎模型中,研究了长双歧杆菌和迟缓乳杆菌属新菌株的治疗潜力。在本研究中,我们的主要目标是确定摄入这些菌株是否能减轻结肠炎症状,如果能,则阐明它们如何恢复肠道微生物平衡并调节微生物代谢功能。在大多数益生菌治疗组中,结肠炎疾病活动指数评分显著改善,结肠长度得以保留,菌株CBA7106和BBH表现出与鼠李糖乳杆菌GG(用作阳性对照)相当的疗效。此外,组织学分析证实炎症减轻,黏膜完整性增强。微生物多样性评估表明肠道微生物组成显著恢复,有益类群如乳酸杆菌和阿克曼氏菌的丰度增加尤为明显。代谢组学分析确定了关键的抗炎代谢物,包括6-羟基己酸、吲哚-3-乳酸和胆碱,这些在益生菌治疗组中显著升高。值得注意的是,使用PICRUSt2进行的功能分析显示铁载体生物合成途径(ko01053)持续下降,这表明这些候选益生菌菌株可能抑制铁载体的产生——病原菌加重肠道炎症的关键机制。综上所述,这些发现表明候选益生菌菌株CBA7106和BBH通过调节肠道微生物群、促进抗炎代谢物的产生和抑制铁载体生物合成,有效减轻DSS诱导的结肠炎。本研究为IBD靶向益生菌疗法的开发提供了有价值的见解,强调了它们作为恢复肠道健康和减轻炎症的补充方法的潜力。有必要进行进一步的临床研究,以在人群中验证这些观察结果。
J Agric Food Chem. 2025-7-2
Cochrane Database Syst Rev. 2023-10-23
Cochrane Database Syst Rev. 2023-2-17
Cochrane Database Syst Rev. 2011-11-9
Cochrane Database Syst Rev. 2022-5-20
J Cachexia Sarcopenia Muscle. 2023-4
Nucleic Acids Res. 2023-1-6
Gastroenterol Res Pract. 2021-11-25